Author

J. Huo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 2 Biophysics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 8 Assay:structural biology· 4 Organism:virus· 4 Organism:mouse· 3 Organism:human· 2 Organism:plant (other)· 2 Approach:statistical model· 2

Frequent Co-Authors

D. Zhou· 5 shared H. M. E. Duyvesteyn· 5 shared D. I. Stuart· 4 shared E. E. Fry· 4 shared J. Ren· 4 shared P. Supasa· 4 shared R. J. Owens· 4 shared G. R. Screaton· 3 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

D. Zhou

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Cardiac fibroblasts regulate cardiomyocyte hypertrophy through dynamic regulation of type I collagen

Q. Meng, S. L. K. Bowers, Y. Kuwabara, J. Huo, R. Minerath, A. J. York, M. A. Sargent, V. Prasad, A. J. Saviola, D. C. Galindo, K. C. Hansen, R. J. Vagnozzi, K. E. Yutzey, J. D. Molkentin

This study shows that type I collagen produced by cardiac fibroblasts regulates cardiomyocyte hypertrophy and fibrosis, with developmental and acute deletion effects on cardiac function.

bioRxiv · May 25, 2022 · PreprintCell Biology

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

A. Tuekprakhon, J. Huo, R. Nutalai, A. Dijokaite-Guraliuc, D. Zhou, H. M. Ginn, M. Sekvaraj, C. Liu, A. J. Mentzer, P. Supasa, H. M. E. Duyvesteyn, R. Das, D. Skelly, T. G. Ritter, A. Amini, , G. R. Screaton

This study shows that BA.4 and BA.5 variants are more resistant to neutralization by vaccine and BA.1 immune sera compared to BA.1 and BA.2.

bioRxiv · May 21, 2022 · PreprintMicrobiology

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

W. Dejnirattisai, J. Huo, D. Zhou, J. Zahradni_k, P. Supasa, C. Liu, H. M. E. Duyvesteyn, H. Ginn, A. J. Mentzer, A. Tuekprakhon, R. Nutalai, B. - Wang, A. Dijokaite, S. Khan, O. Avinoam, , Mad

This study shows that Omicron-B.1.1.529 has extensive mutations in Spike that reduce neutralization by antibodies from vaccinated and previously infected individuals, and escape most monoclonal antibodies.

bioRxiv · Dec 3, 2021 · PreprintMicrobiology

Cryptic pathogen-sugar interactions revealed by universal saturation transfer analysis

C. J. Buchanan, B. Gaunt, P. J. Harrison, Y. Yang, J. Liu, A. Khan, A. M. Giltrap, A. Le Bas, P. N. Ward, K. Gupta, M. Dumoux, S. Daga, N. Picchiotti, M. Baldassarri, E. Benetti, , B. G. Davis

This paper introduces uSTA, an NMR method to analyze protein-ligand interactions, revealing SARS-CoV-2 spike binds sialoside sugars via the NTD and showing variants-of-concern lose this binding.

bioRxiv · Apr 14, 2021Biophysics

Architecture of cell-cell junctions in situ reveals a mechanism for bacterial biofilm inhibition

C. Melia, J. R. Bolla, S. Katharios-Lanwermeyer, D. Mihaylov, P. Hoffmann, J. Huo, M. Wozny, L. Elfari, J. Boehning, R. Owens, C. V. Robinson, G. O'Toole, T. Bharat

The paper reveals the structure and function of CdrA in Pseudomonas aeruginosa biofilms, showing how it mediates cell-cell interactions and how targeting it can inhibit biofilm formation.

bioRxiv · Feb 8, 2021Microbiology

Neutralization of SARS-CoV-2 by destruction of the prefusion Spike

J. Huo, Y. Zhao, J. Ren, D. Zhou, H. M. E. Duyvesteyn, H. M. Ginn, L. Carrique, T. Malinauskas, R. R. Ruza, P. N. Shah, T. K. Tan, P. Rijal, N. Coombes, K. Bewley, J. Radecke, , D. I. Stuart

This paper identifies CR3022 as a monoclonal antibody that neutralizes SARS-CoV-2 by destroying its prefusion Spike conformation, suggesting therapeutic potential.

Cell Host & Microbe · Sep 1, 2020Peer-reviewedMicrobiology

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

T. K. Tan, P. Rijal, R. Rahikainen, A. Keeble, L. Schimanski, S. Hussain, R. Harvey, J. Hayes, J. Edwards, R. McLean, V. Martini, M. Pedrera, N. Thakur, C. Conceicao, I. Dietrich, , R. Owens

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

bioRxiv · Aug 31, 2020Immunology

The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer

L. Carrique, H. M. E. Duyvesteyn, T. Malinaukas, Y. Zhao, J. Ren, D. Zhou, T. S. Walter, J. Radecke, J. Huo, R. Ruza, P. N. Shah, E. E. Fry, D. I. Stuart

The paper identifies a lipid-binding pocket in the SARS-CoV-2 Spike that stabilizes the prefusion trimer and shields neutralizing epitopes, suggesting it as a potential drug target.

bioRxiv · Aug 13, 2020 · PreprintMicrobiology

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

S. P. Graham, R. K. McLean, A. J. Spencer, S. Belij-Rammerstorfer, D. Wright, M. Ulaszewska, J. C. Edwards, J. W. P. Hayes, V. Martini, N. Thakur, C. Conceicao, I. Dietrich, H. Shelton, R. Waters, A. Ludi, , T. Lambe

This study evaluates the immunogenicity of single and booster doses of the ChAdOx1 nCoV-19 vaccine in mice and pigs, finding that a booster significantly enhances antibody responses, especially in pigs.

bioRxiv · Jun 20, 2020Immunology

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

D. Zhou, H. M. E. Duyvesteyn, C.-P. Chen, C.-G. Huang, T.-H. Chen, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, S.-H. Cheng, Y.-C. Huang, T.-Y. Lin, C. Ma, J. Huo, L. Carrique, T. Malinauskas, , K.-Y. A. Huang

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

bioRxiv · Jun 12, 2020Microbiology